Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.